In a previous article published recently in CMI [1], it was shown that all clinical isolates of Escherichia coli resistant to cefoxitin were also resistant to amoxycillin-clavulanate. In contrast, preliminary results from a study performed in Seville (Spain) indicated that 34.4% of cefoxitin-resistant clinical isolates of E. coli remained susceptible to amoxycillin-clavulanate (43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract C2-97). Resistance to cefoxitin in clinical isolates of E. coli has been associated with hyperproduction of chromosomal or plasmid-borne AmpC-type b-lactamases [1-3]. Clavulanic acid is not a good substrate for these enzymes, so it might be expected that strains of E. coli overproducing AmpC b-lactamase would be resistant to cefoxitin and amoxycillin-clavulanate. We would like to report on the frequency of these resistance phenotypes among isolates of E. coli from hospitals located in Europe, Asia and America that are included in the Sentry Antimicrobial Surveillance Program.
10.5% and 22.1% in Asia-West Pacific. Table 1 shows the frequencies of the four possible phenotypic combinations of susceptibility-resistance to cefoxitin and amoxycillin-clavulanate. The frequencies of the four phenotypes in Europe were similar to those for isolates from North America, Latin America and the Asia-Pacific regions. As has been observed in previous studies [5, 6] , susceptibility to amoxycillin-clavulanate was more common among cefoxitin-susceptible isolates than among cefoxitin-resistant isolates of E. coli. Resistance to amoxycillinclavulanate was common among cefoxitin-resistant isolates (67.4-70.8%). A high percentage of cefoxitin-resistant isolates remained susceptible to amoxycillin-clavulanate, suggesting that a new phenotype of resistance to cefoxitin is emerging worldwide. Although the mechanism(s) of resistance to cefoxitin (possibly involving changes in outer-membrane proteins or altered penicillin-binding proteins) in E. coli isolates with this phenotype is currently under investigation, it cannot be explained simply by the hyperproduction of AmpC, since this enzyme, when overproduced, confers resistance or decreased susceptibility to amoxycillin-clavulanate. FOX-R, resistance to cefoxitin; FOX-S, susceptibility to cefoxitin; AMC-R, resistance to amoxycillin-clavulanate; AMC-S, susceptibility to amoxycillin-clavulanate.
